These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3742482)

  • 1. Nuclear magnetic resonance investigation of erythrocyte membranes in chronic myeloproliferative disorders.
    Morariu VV; Petrov L
    Cancer Biochem Biophys; 1986 Jul; 8(3):203-9. PubMed ID: 3742482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The uptake of manganese ions and the apparent thermal transition of the erythrocyte membranes.
    Morariu VV; Ionescu MS; Frangopol M; Grosescu R; Lupu M; Frangopol PT
    Biochim Biophys Acta; 1986 Aug; 860(1):155-8. PubMed ID: 3730383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased erythrocyte susceptibility to lipid peroxidation in myeloproliferative disorders.
    Gilbert HS; Roth EF; Ginsberg H
    J Lab Clin Med; 1984 Jan; 103(1):6-13. PubMed ID: 6690640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear magnetic resonance investigation of human erythrocytes in the presence of manganese ions. Evidence for a thermal transition.
    Morariu VV; Ionescu MS; Frangopol M; Grosescu R; Lupu M; Frangopol PT
    Biochim Biophys Acta; 1985 May; 815(2):189-95. PubMed ID: 3995023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
    Thiele J; Funke S; Holgado S; Choritz H; Georgii A
    Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythrocyte-plasma water exchange studied by nuclear magnetic resonance spin-spin (T2) relaxation. Relation between the time the water molecule stays in the erythrocyte and its volume].
    Teyssier R; Peyrin JO
    C R Seances Soc Biol Fil; 1986; 180(3):330-6. PubMed ID: 2946378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reduced glutathione (GSH) in erythrocytes in myeloproliferative diseases].
    Benöhr HC; Tigges FJ; Waller HD
    Verh Dtsch Ges Inn Med; 1973; 79():461-3. PubMed ID: 4790261
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J; Kvasnicka HM; Vardiman J
    Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo platelet release in myeloproliferative disorders.
    Ireland H; Lane DA; Wolff S; Foadi M
    Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of temperature on water diffusion in human erythrocytes and ghosts--nuclear magnetic resonance studies.
    Benga G; Pop VI; Popescu O; Hodârnău A; Borza V; Presecan E
    Biochim Biophys Acta; 1987 Dec; 905(2):339-48. PubMed ID: 2825782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL
    Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leukocyte alkaline phosphatase and glucose-6-phosphate-dehydrogenase of the erythrocytes in differential diagnosis of chronic myeloproliferative diseases (author's transl)].
    Hennemann HH; Schief A
    Med Klin; 1974 Aug; 69(34):1359-63. PubMed ID: 4530151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.